United States Oral Thin Films Market expected to grow at a high CAGR during 2024-2031 | Top Companies - ZIM Laboratories Limited, Aquestive Therapeutics Inc, IntelGenx Corp

"Oral Thin Films Market is expected to grow at a high CAGR during the forecasting period (2024-2031)." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/oral-thin-films-market?sp

United States: Recent Industry Developments

✅ In June 2025, Aquestive Therapeutics, Inc. announced that its New Drug Application for Anaphylm (epinephrine) sublingual film was accepted by the U.S. Food & Drug Administration with a target action date of January 31 2026, seeking to treat type-1 allergic reactions including anaphylaxis. The product represents a major expansion of OTF formats into emergency care and allergen management. It reflects the broader trend toward patient-friendly, fast-dissolving dosage forms that bypass traditional tablets.

✅ In April 2025, ZIM Laboratories Limited signed a licensing agreement with Globalpharma Co. (L.L.C.) to license its ThinOral platform for the registration and supply of ten OTF-based pharmaceutical and nutraceutical products geared to GCC region patients. The deal underscores growing geographic expansion and willingness to adopt thin-film technology in emerging markets. It highlights that OTF technology is transitioning from niche formats into wider regional manufacturing and supply-chain initiatives.

✅ In 2025, market research indicated that the OTF market is experiencing double-digit growth, driven by rising demand for child- and geriatric-friendly drug delivery systems, increasing chronic disease prevalence, and advances in solvent-casting, hot-melt and 3-D printing film technology. The advantage of rapid onset and convenience is strongly favouring OTF adoption in neurological, pain management and opioid-dependence therapies. It illustrates how delivery-format innovation is accelerating alongside broader pharmaceutical investment.

✅ In 2024, key pharmaceutical players focused on material and polymer innovations-such as improving moisture-barriers, enhancing API-loading capacity and advancing mucoadhesive/buccal film technologies-to make OTFs more robust, cost-effective and manufacturable at scale. These improvements help make films viable alternatives to tablets and capsules, especially in regions where patient compliance is a challenge. The shift signals increasing maturity of the OTF value chain and manufacturing base.

Asia-Pacific: Recent Industry Developments

✅ In 2025, Asia-Pacific regions including India and China are forecast to experience the fastest growth in OTF demand, with growth rates exceeding 10 % annually, supported by expanding e-pharmacy channels, increased acceptance of novel dosage forms and rising middle-class healthcare spending. The region is becoming both a manufacturing hub and a high-growth market for OTFs. It underscores the global supply-chain shift toward emerging market adoption and localised manufacturing.

✅ In 2024-25, regional formulators in India began developing disease-specific OTFs (for migraine, nausea, paediatric indications) using solvent-casting and printing technologies, aiming to address swallowability issues in children and elderly patients. The production focus is shifting from only global players to localised manufacturers adapting the format to regional needs. It emphasises how localisation of OTF development is becoming a differentiator in emerging markets.

✅ In 2025, contract manufacturing and CDMO firms in India began investing in OTF production assets, including film-casting lines and packaging designed for film strips, to meet OTF formulation demand and serve export markets. These investments indicate build-out of local manufacturing capacity for OTFs beyond simple tablets. It supports the notion that emerging markets will increasingly host full OTF value chains rather than only serve as end-markets.

✅ In 2024, regulatory and standardisation authorities in the Asia-Pacific region started to issue more guidance on thin-film delivery formats, encouraging OTF adoption for niche therapies and non-traditional dosage forms; this regulatory support helps address barriers such as stability, dosing uniformity and moisture sensitivity of films. The increased regulatory alignment helps de-risk OTF commercialization in the region.

Oral Thin Films Market: Drivers

The oral thin films market is growing rapidly as it offers a convenient, fast-acting, and patient-friendly alternative to traditional drug delivery forms such as tablets and capsules. These films, designed to dissolve quickly in the mouth without water, are increasingly used for delivering prescription drugs, vitamins, and nutraceuticals. Rising demand for pain-free and easy-to-administer dosage forms, especially among pediatric and geriatric populations, is a key growth driver. The pharmaceutical industry's focus on improving bioavailability and onset time of medications is also fueling adoption. Moreover, advancements in film-forming polymers, taste-masking technologies, and solvent casting methods are enhancing product performance and expanding therapeutic applications.

The growing prevalence of chronic conditions such as migraines, nausea, and central nervous system disorders is creating new opportunities for oral thin film formulations. Companies are investing in R&D to develop films for controlled release, multi-layer delivery, and combination drugs. The nutraceutical and over-the-counter (OTC) segments are also witnessing strong uptake due to consumer preference for portable and discreet dosage formats. Additionally, regulatory approvals and patent expirations of conventional drugs are opening pathways for innovation and generic product launches. With its blend of convenience, efficacy, and patient compliance, the oral thin films market is positioned for robust, technology-driven growth in the years ahead.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oral-thin-films-market?sp

Oral Thin Films Market: Major Players

ZIM Laboratories Limited, Aquestive Therapeutics Inc, IntelGenx Corp, C.L. Pharm, Cure Pharmaceutical, LTS Lohmann Therapie-Systeme AG, Viatris Inc, NAL Pharma, Sunovion Pharmaceuticals, Inc, DK Livkon Pvt. LTD.

Segment Covered in the Oral Thin Films Market:

By Product
The market is segmented into Sublingual Film and Fast Dissolving Dental/Buccal Film. Sublingual films hold the dominant share due to their rapid onset of action and enhanced bioavailability, while buccal films are gaining traction for their ease of administration and patient compliance.

By Disease Indication
Based on disease indication, the market includes Migraine, Schizophrenia, Opioid Dependence, Nausea and Vomiting, and Other Disease Indications. Opioid dependence leads the segment due to the rising prevalence of substance abuse and growing adoption of sublingual formulations in de-addiction therapies.

By Distribution Channel
Distribution channels comprise Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels. Hospital pharmacies dominate owing to higher prescription rates and availability of specialty drugs, whereas retail pharmacies are expanding rapidly with the growing accessibility of oral thin film medications.

Research Process:

Both primary and secondary data sources have been used in the Oral Thin Films Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Oral Thin Films Market Research Industry:

➠ Who leads the Oral Thin Films industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Oral Thin Films market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Oral Thin Films market growth?
➠ What are the dominant sales and distribution strategies in the Oral Thin Films industry?

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=oral-thin-films-market
(Purchase 2 or more Repots and get 50% Discount)

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.